|06/12/17||Coherus BioSciences Receives Complete Response Letter from FDA for its Biologics License Application for CHS-1701 (Pegfilgrastim Biosimilar Candidate)|
|Management to host a call today at 8:00 a.m. EDT to discuss FDA feedback
REDWOOD CITY, Calif., June 12, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (NASDAQ:CHRS), today announced that the U.S. Food and Drug Administration (“FDA”) has issued a complete response letter (“CRL”) for its biologics license application (“BLA”) for CHS-1701, a pegfilgrastim (Neulasta®) biosimilar candidate, under the 351(k) pathway.
The CRL primarily focused on the FDA request for a reanalysis of a subset of ... |
|06/01/17||Coherus BioSciences Management to Present at 36th NASDAQ OMX Investor Program |
|REDWOOD CITY, Calif., June 01, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that senior management will present at the 36th NASDAQ OMX Investor Program on Thursday, June 15, 2017 in London, UK at 11:30 am GMT.
The audio portion of the presentations will be available on the investors page of the Coherus BioSciences website at http://investors.coherus.com.
About Coherus BioSciences, Inc.
Coherus is a leading pure-play, global biosimilar company that dev... |
|05/16/17||Coherus BioSciences Prevails in ‘135 IPR Decision|
|Patent Trial and Appeal Board Invalidates AbbVie U.S. Patent 8,889,135
REDWOOD CITY, Calif., May 16, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that the Patent Trial and Appeal Board (“PTAB”) of the U.S. Patent and Trademark Office ruled in favor of Coherus’ petitions for Inter Partes Review (“IPR”) of AbbVie’s U.S. Patent 8,889,135 (the ‘135 Patent). The PTAB’s decision invalidates all claims of the patent that were directed to a method for treating rh... |
|05/08/17||Coherus BioSciences Reports First Quarter 2017 Corporate Highlights and Financial Results|
|REDWOOD CITY, Calif., May 08, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (NASDAQ:CHRS), today reviewed corporate events and reported financial results for the quarter ended March 31, 2017.
Corporate Highlights for the First Quarter 2017 Include:
Immunology (anti-TNF) therapeutic franchise:
CHS-1420 (adalimumab (Humira®) biosimilar candidate)
Reported positive topline 24-week treatment results for CHS-1420 in patients with psoriasis.
Announced filing of four petiti... |